StemExpress was founded in 2010 to accelerate the cure and prevention of significant medical conditions at life-changing speed. StemExpress supports cell and gene therapies, commercialization of disease specific treatments, medical research, clinical trials, precision/regenerative medicine, among other researchers and clinicians around the world who are developing and implementing revolutionary treatments and cures. StemExpress is currently the nation's leading biospecimen provider of human primary cells, stem cells, human bone marrow, cord blood, peripheral blood, maternal blood, and disease-state products for academic, biotechnological, diagnostic, pharmaceutical and contract research organizations. StemExpress is registered with the U.S. Food and Drug Administration (FDA) and has seven (7) independently owned and operated brick-and mortar cellular clinics across the United States to collect blood, cells and tissue from patients and donors. These clinics include state-of-the-art cell manufacturing laboratories for clinical and research purposes, and CLIA certified/high-complexity diagnostics. In response to the global COVID-19 pandemic, StemExpress launched and continues to offer a highly successful end-to-end testing solution that includes on-line patient registration, scheduling, specimen collection, pop-up site management, mobile testing units, and laboratory services using gold-standard PCR testing at high-volume capacity with rapid turn-around times. As part of this response to COVID-19, StemExpress directly and proudly supports frontline workers, inner city communities, hospitals, skilled nursing facilities, school districts, correctional facilities, utility companies, major league sports, tribal territories and territorial governments, among others, across the globe. #celltherapy #genetherapy #primarycells #immunotherapy #immunology #cancerresearch #biotechnology #biospecimens #cancerresearch #biomedicalresearch #stemcellresearch #covidtesting